Biomarkers of treatment response in rheumatoid arthritis: from conventional markers to tissue immunophenotype

• by N.A. Batashkov, E.V. Gerasimova, D.A. Gerasimova, D.V. Svetlichnyy, E.S. Petryakina, D.I. Tychinin, S.M. Yudin, V.S. Yudin, A.A. Keskinov, V.P. Bogdanov, E.G. Zotkin, A.M. Lila, D.V. Tabakov, M. Woroncow, V.I. Skvortsova, P.Yu Volchkov

• July 17, 2026

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

• by Kathryn Wighton

• June 11, 2026

• 2 min

Radon balneotherapy in rheumatologic diseases: potential mechanisms and implications for cardiovascular autonomic control and inflammation

• by Gabriel D. Rodrigues, Earric Lee, Benoit Dugué, Christian Hanshans, Maria Chiara Maccarone, Konstantinos Triantafyllias, Arnulf Hartl, Eugenijus Kaniusas, Sabrina Mörkl, Thomas E. Schmid, Goda-Camille Mickeviciute, Hannes Untner, Werner Klingler, Martin Offenbächer

• June 24, 2026

Serostatus May Modify RA Activity–CV Link

Combined rheumatoid factor and anticitrullinated protein antibody status appeared to modify the association between baseline rheumatoid arthritis disease activity and subsequent cardiovascular events in an international observational cohort.

• by Andrea Surnit

• July 15, 2026

• 4 min